Immune Biomarkers

Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Task Force has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field.

Topics being addressed by individual working groups include:

  • Validation of candidate biomarkers
  • Identification of the most promising technologies
  • Testing of high throughput immune signatures
  • Investigation of the pre-treatment tumor microenvironment

Task Force Members

View current and past Task Force members via the links below:

Dr. Lisa Butterfield on SITC Immune Biomarkers Task Force

In the video below, watch as current SITC President Dr. Lisa Butterfield discusses the Immune Biomarkers Task Force.


Working Group White Papers

Working Group 1

Validation of Biomarkers to Predict Response to Immunotherapy in Cancer (two-part white paper)
Journal for ImmunoTherapy of Cancer, November 2016

Working Group 2

Novel Technologies and Emerging Biomarkers for Personalized Cancer Immunotherapy
Journal for ImmunoTherapy of Cancer, January 2016

Working Group 3

Coming Soon

Working Group 4

Coming Soon

Immune Monitoring Technology Primers

Click here to view a complete list of current and past published Immune Monitoring Technology Primers in the Journal for ImmunoTherapy of Cancer (JITC).

Past Manuscripts

SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery
Journal of Translational Medicine, September 2011

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Clinical Cancer Research, May 2011

Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc/SITC Biomarker Taskforce
Journal of Translational Medicine, December 2010

A Systematic Approach to Biomarker Discovery; Preamble to "the iSBTc-FDA Taskforce on Immunotherapy Biomarkers"
Journal of Translational Medicine, December 2008


Immunotherapy Biomarkers 2016: Overcoming the Barriers

NCI/CCR and SITC co-sponsored a 2016 Biomarkers meeting to review the state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward. The main goals were to provide updated information to a wide audience and solicit stakeholder participation in promoting successful immune biomarker research.

Click here for more information about this 2016 event.